Pfizer Corporation

Eugene Lvovich Piatnitski Chekler

Patrick Robert Verhoest

Adam Matthew Gilbert

Rayomand Jal Unwalla

James Thomas Anderson

Edmund Lee Ellsworth

Anthony P Ricketts

Roberta Louise Dorow

Jeffrey Braden Sperry

Bruce Kipp Erickson

David P Thompson

The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or &#x2014;CR&#x2014;, where Ris hydrogen, C-Clinear or branched chain alkyl, etc., Z is &#x2014;CR&#x2014;, or, &#x2014;N&#x2014;, where Ris hydrogen, C-Clinear or branched chain alkyl, etc.; Ris hydrogen, C-Clinear or branched chain alkyl, etc.; Rare independently hydrogen or C-Clinear or branched chain alkyl; Rand Rare independently hydrogen, C-Clinear or branched chain alkyl, etc.; Rand Rare independently hydrogen or C-Clinear or branched chain alkyl, etc.; Ris hydrogen, C-Clinear or branched chain alkyl, etc.; Rand Rare independently hydrogen or C-Clinear or branched chain alkyl, etc.; Q is &#x2014;CO&#x2014;, &#x2014;(CH)&#x2014;, &#x2014;(CHR)&#x2014;, or &#x2014;(CRR)&#x2014;, where Rand Rare independently C-Clinear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, for the treatment of certain diseases, particularly those affected or mediated by the androgen receptor; to combinations comprising such compounds with a second pharmaceutically active ingredient; to compositions containing such combinations; and to such combinations for the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.

Methods of use and combinations

This invention relates to a novel crystalline form of 6-[(4R)-4-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile which is useful as a selective androgen receptor modulator (SARM), and to compositions thereof and suitable processes for the preparation thereof.

Crystalline form of 6-[(4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]iosoquinoline-1-carbonitrile

The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or &#x2014;CR&#x2014;, where Ris hydrogen, C-Clinear or branched chain alkyl, etc., Z is &#x2014;CR&#x2014;, or, &#x2014;N&#x2014;, where Ris hydrogen, C-Clinear or branched chain alkyl, etc.; Ris hydrogen, C-Clinear or branched chain alkyl, etc.; Rare independently hydrogen or C-Clinear or branched chain alkyl; Rand Rare independently hydrogen, C-Clinear or branched chain alkyl, etc.; Rand Rare independently hydrogen or C-Clinear or branched chain alkyl, etc.; Ris hydrogen, C-Clinear or branched chain alkyl, etc.; Rand Rare independently hydrogen or C-Clinear or branched chain alkyl, etc.; Q is &#x2014;CO&#x2014;, &#x2014;(CH)&#x2014;, &#x2014;(CHR)&#x2014;, or &#x2014;(CRR)&#x2014;, where Rand Rare independently C-Clinear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.

Selective androgen receptor modulators

Growing community of inventors

Concord, MA, United States of America

Eugene Lvovich Piatnitski Chekler